HOME >> BIOLOGY >> NEWS
Multiple Chemical Sensitivity: A 1999 consensus

The Archives of Environmental Health announces publication of the first consensus definition of the controversial syndrome known as multiple chemical sensitivity (MCS). The 1999 Consensus on MCS, signed by 34 medical researchers and clinicians from the United States and Canada, appears in the May/June 1999 issue (volume 54, number 3). It defines MCS according to six criteria, the first five of which were identified in a survey of 89 clinicians representing a diverse range of medical specialties and opinions that the Archives published in 1993 (see Nethercott JR, Davidoff LL, Curbow B and Abbey H. 1993. Multiple chemical sensitivities syndrome: toward a working case definition. Arch Environ Health 48: 1926.) 1999 Consensus Criteria for Multiple Chemical Sensitivity

  1. The symptoms are reproducible with repeated [chemical] exposure.

  2. The condition is chronic.

  3. Low levels of exposure [lower than previously or commonly tolerated] result in manifestations of the syndrome.

  4. The symptoms improve or resolve when the incitants are removed.

  5. Responses occur to multiple chemically unrelated substances.

  6. Symptoms involve multiple organ systems.

The prior lack of any consensus definition has been a significant obstacle to the diagnosis of MCS in clinical practice. This definition is published with the hope that it may standardize the diagnosis of MCS in both clinical and research settings. According to epidemiological surveys conducted by the New Mexico Department of Health and California Department of Health Services, one sixth of randomly selected adults are adversely affected by chemical sensitivity to some degree, while 2% (in NM) to 8% in CA) say they have already been diagnosed with MCS by a medical professional. Dr. Kaye Kilburn, editor of the Archives of Environmental Health and one of the authors of the consensus, hailed the new MCS definition as a practical and orderly step that was overdue. Altho
'"/>

Contact: Ms. Pat McCready
aeh@heldref.org
301-384-0598
Heldref Publications
1-Jul-1999


Page: 1 2

Related biology news :

1. A new discovery by scientists at the MNI may provide insights into Multiple Sclerosis
2. Multiple lifestyle changes effectively lower blood pressure
3. Multiple factors affect flight power curves among species
4. Multiple births - their risks and how to prevent them
5. Multiple studies show that psyllium lowers cholesterol
6. Researcher Awarded Patent For System To Fight Multiple Diseases
7. Scientists Find Multiple New Uses For Worn-Out Tires
8. Relapses Prevented In Mouse Model Of Multiple Sclerosis: Research Aimed At Treating Relapses In Human MS
9. Protein Implicated In Multiple Sclerosis
10. Discovery By Fertility Specialist Offers Promise Of Reducing Multiple BirthsTied To Fertility Treatment
11. Common Cold Caused By Multiple Viruses

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Multiple Chemical Sensitivity consensus

(Date:4/1/2015)... 2015   Medisafe ™, the leading global medication ... iOS and Android smartphones and tablets, ... the platform to allow patients to track and correlate ... time, patients will be able to visualize in real-time ... biometrics, such as glucose levels and blood pressure. ...
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... of the "Global Gesture Recognition Market in Automotive ... The analysts forecast the Global Gesture Recognition market in ... over the period 2013-2018. Gesture recognition is ... to different gestures of an individual. Gesture recognition technology ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... and Voice Biometrics - Global Strategic Business Report" report to ... Face and Voice Biometrics in US$ Thousands by the following Segments: ... for the US, Canada , Japan ... , Middle East & Africa ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
(Date:4/16/2015)... (PRWEB) April 16, 2015 Capillus, ... distribution and physician network in Europe and Asia. ... has appointed Fernando Bermúdez, former Business Development Director ... An industry veteran, Mr. Bermúdez’s professional achievements include ... in Spain, while also penetrating the Portuguese marketplace ...
(Date:4/16/2015)... OncoTAb, Inc., a ... spin-out company, announced today the appointment of physician ... Chief Operating Officer (COO). Cooper brings to OncoTAb ... clinical diagnostic and biotechnology platforms in the fields ... extensive career transcends the field of medical and ...
(Date:4/16/2015)... 2015 /CNW/ - Bioenterprise Corporation is pleased to announce that ... Charlottetown , PEI.  Bioenterprise has established a ... Council for the commercialization of agricultural technologies and innovations. ... PEI ADAPT.  They have been at the heart of ... explains Dave Smardon , President & CEO of ...
(Date:4/16/2015)... -- Avelas Biosciences, an in vivo cancer ... that it has initiated a Phase 1b study of ... primary, non-recurrent breast cancer undergoing surgery. In commencing the ... Steven Chen , M.D., as vice president of ... study will enroll up to 39 women with stage ...
Breaking Biology Technology:Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2OncoTAb Names Dr. David L. Cooper as COO 2Bioenterprise Corporation Expands into the Maritimes 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3
Cached News: